Claims for Patent: 10,143,677

Summary for Patent: 10,143,677

Title:	Taxane analogs for the treatment of brain cancer
Abstract:	Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
Inventor(s):	McChesney; James D. (Etta, MS), Tapolsky; Gilles H. (Louisville, KY), Emerson; David L. (Longmont, CO), Marshall; John (Washington, DC), Kurman; Michael (Upper Saddle River, NJ), Modiano; Manuel (Tuscon, AZ)
Assignee:	TAPESTRY PHARMACEUTICALS, INC. (Atlanta, GA)
Application Number:	15/483,551
Patent Claims:	1. A method of treating brain cancer in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a compound of Formula (1), and a liquid vehicle ##STR00024## 2. The method of claim 1, wherein the compound of Formula (1) is a compound of Formula S-(1) ##STR00025## 3. The method of claim 1, wherein the compound of Formula (1) is a compound of Formula R-(1) ##STR00026## 4. The method of claim 1, wherein the brain cancer is glioblastoma. 5. The method of claim 1, wherein the pharmaceutical composition comprising a compound of Formula (1) is administered intravenously. 6. The method of claim 1, wherein the pharmaceutical composition comprising a compound of Formula (1) is administered repeatedly. 7. The method of claim 6, wherein two successive administrations of the pharmaceutical composition comprising a compound of Formula (1) are separated by about seven days. 8. The method of claim 6, wherein two successive administrations of the pharmaceutical composition comprising a compound of Formula (1) are separated by about twenty-one days. 9. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of between 7 mg/m.sup.2 and 500 mg/m.sup.2, between 7 mg/m.sup.2 and 240 mg/m.sup.2, or between 7 mg/m.sup.2 and 185 mg/m.sup.2. 10. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of at least 30 mg/m.sup.2, at least 50 mg/m.sup.2, at least 80 mg/m.sup.2, at least 100 mg/m.sup.2, or at least 150 mg/m.sup.2. 11. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 7 mg/m.sup.2. 12. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 14 mg/m.sup.2. 13. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 28 mg/m.sup.2. 14. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 56 mg/m.sup.2. 15. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 84 mg/m.sup.2. 16. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 85 mg/m.sup.2. 17. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 126 mg/m.sup.2. 18. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 127.5 mg/m.sup.2. 19. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 160 mg/m.sup.2. 20. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose greater than 160 mg/m.sup.2. 21. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose of about 185 mg/m.sup.2. 22. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose greater than 185 mg/m.sup.2. 23. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose less than 250 mg/m.sup.2. 24. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose greater than 160 mg/m.sup.2 and less than 250 mg/m.sup.2. 25. The method of claim 1, wherein the pharmaceutical composition is administered at a compound of Formula (1) dose greater than 185 mg/m.sup.2 and less than 250 mg/m.sup.2. 26. The method of claim 1, further comprising administering to the mammal an additional pharmaceutical composition comprising a chemotherapeutic agent or a monoclonal antibody. 27. The method of claim 26, wherein the additional pharmaceutical composition is administered on the day of, or within 3 days of administration of the pharmaceutical composition comprising a compound of Formula (1). 28. The method of claim 26, wherein the chemotherapeutic agent is temozolomide. 29. The method of claim 26, wherein the monoclonal antibody is bevacizumab. 30. The method of claim 1, wherein the compound of Formula (1) has a concentration between 0.1 mg/ml and 15 mg/ml in the pharmaceutical composition. 31. The method of claim 1, wherein the liquid vehicle comprises ethanol. 32. The method of claim 1, wherein the liquid vehicle comprises polyethoxylated castor oil.

Details for Patent 10,143,677

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2027-02-28